One clinical trial assessed the approach of combining nivolumab or placebo with bevacizumab plus platinum-based chemotherapy for treatment of NSCLC patients without driver mutations in ALK, EGFR, or ROS1, evaluated the safety and effectiveness in the treatment plan [24]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.